18275655. AMIDES AS CBL-B INHIBITORS simplified abstract (Genentech, Inc.)

AMIDES AS CBL-B INHIBITORS

Organization Name

Genentech, Inc.

Inventor(s)

Jun Liang of Los Altos Hills CA (US)

Araz Jakalian of Montreal (CA)

Michael John Lambrecht of Burlingame CA (US)

Robin Larouche-gauthier of Montreal (CA)

Malcolm Huestis of San Francisco CA (US)

Man Un Ung of San Mateo CA (US)

Xiaojing Wang of Belmont CA (US)

Arun Yadav of Montreal (CA)

Jason Robert Zbieg of Montara CA (US)

Fabio Broccatelli of San Diego CA (US)

AMIDES AS CBL-B INHIBITORS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18275655 titled 'AMIDES AS CBL-B INHIBITORS

The abstract of the patent application discusses various amide compounds that bind to Cbl-B, with a focus on those selective for C-Cbl, along with methods of production and application.

• Amide compounds binding to Cbl-B, including selective ones for C-Cbl, are highlighted.
• Methods for making and using these compounds are detailed.
• Representative molecules within specific formulae are mentioned.

Potential Applications: - Treatment of diseases related to Cbl-B dysregulation. - Development of targeted therapies for specific types of cancer. - Research in the field of protein-protein interactions.

Problems Solved: - Targeting specific Cbl proteins for therapeutic purposes. - Enhancing the effectiveness of treatments by focusing on selective binding.

Benefits: - Improved precision in drug targeting. - Potential for personalized medicine approaches. - Advancements in understanding protein interactions.

Commercial Applications: Title: "Innovative Amide Compounds for Targeted Therapies in Cancer Treatment" This technology could revolutionize the development of cancer treatments by targeting specific proteins involved in the disease process. The market implications are significant, with the potential for tailored therapies based on individual patient profiles.

Questions about the technology: 1. How do these amide compounds specifically target Cbl-B and C-Cbl proteins? 2. What sets these compounds apart from existing treatments targeting similar proteins?

Frequently Updated Research: Stay updated on the latest advancements in the field of protein-protein interactions and targeted therapies for cancer treatment to ensure the most current information on this innovative technology.

Original Abstract Submitted

Various amide compounds that bind Cbl-B, including those that are selective for C-Cbl, and methods of making and using the same. Representative amide compounds include molecules falling within the following formulae: